Risk factors of metabolic bone disease of prematurity

Supamit Ukarapong, Sunil Kumar Batlahally Venkatarayappa, Cristina Navarrete, Gary Berkovitz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective To identify the factors that increase risk of metabolic bone disease of prematurity (MBD). Study design A retrospective case-control study of infants born between January 2013–April 2014 with gestation age < 30 weeks and birth weight < 1000 g. MBD was defined as serum alkaline phosphatase above 500 U/L and characteristic radiographic changes. Information was obtained on the presence of specific comorbidities. Results Of 76 infants evaluated, 40 met criteria for MBD. Median gestational age was 25 weeks in both groups (p = 0.512). Median birth weight of infants with MBD was significantly lower than that of controls (560 vs. 765 g, p < 0.01). Longer period of parenteral nutrition and dexamethasone use was observed in MBD group. Cholestasis was associated with the highest likelihood of MBD (OR 16.6, 95% CI 4.8–56.9). Seizures (OR 5.2, 95% CI 1.3–20.5) and the prolonged use of diuretics (OR 2.6, 95% CI 1.0–7.0) also significantly increased the likelihood of MBD. Only cholestasis remained significant (OR 9.6, 95% CI 2.1–45.3) after multiple regression analysis. Conclusion Cholestasis is a significant risk factor for the development of MBD. Our future studies will be directed towards determining the causal relationship between cholestasis and MBD.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalEarly Human Development
Volume112
DOIs
StatePublished - Sep 1 2017

Fingerprint

Metabolic Bone Diseases
Cholestasis
Birth Weight
Parenteral Nutrition
Diuretics
Dexamethasone
Gestational Age
Alkaline Phosphatase
Case-Control Studies
Comorbidity
Seizures
Regression Analysis
Pregnancy

Keywords

  • Bone
  • Preterm infant
  • Risk factor and comorbidities

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Risk factors of metabolic bone disease of prematurity. / Ukarapong, Supamit; Venkatarayappa, Sunil Kumar Batlahally; Navarrete, Cristina; Berkovitz, Gary.

In: Early Human Development, Vol. 112, 01.09.2017, p. 29-34.

Research output: Contribution to journalArticle

@article{a9cfc39bdffe4dfda045bcf5a00f59b3,
title = "Risk factors of metabolic bone disease of prematurity",
abstract = "Objective To identify the factors that increase risk of metabolic bone disease of prematurity (MBD). Study design A retrospective case-control study of infants born between January 2013–April 2014 with gestation age < 30 weeks and birth weight < 1000 g. MBD was defined as serum alkaline phosphatase above 500 U/L and characteristic radiographic changes. Information was obtained on the presence of specific comorbidities. Results Of 76 infants evaluated, 40 met criteria for MBD. Median gestational age was 25 weeks in both groups (p = 0.512). Median birth weight of infants with MBD was significantly lower than that of controls (560 vs. 765 g, p < 0.01). Longer period of parenteral nutrition and dexamethasone use was observed in MBD group. Cholestasis was associated with the highest likelihood of MBD (OR 16.6, 95{\%} CI 4.8–56.9). Seizures (OR 5.2, 95{\%} CI 1.3–20.5) and the prolonged use of diuretics (OR 2.6, 95{\%} CI 1.0–7.0) also significantly increased the likelihood of MBD. Only cholestasis remained significant (OR 9.6, 95{\%} CI 2.1–45.3) after multiple regression analysis. Conclusion Cholestasis is a significant risk factor for the development of MBD. Our future studies will be directed towards determining the causal relationship between cholestasis and MBD.",
keywords = "Bone, Preterm infant, Risk factor and comorbidities",
author = "Supamit Ukarapong and Venkatarayappa, {Sunil Kumar Batlahally} and Cristina Navarrete and Gary Berkovitz",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.earlhumdev.2017.06.010",
language = "English (US)",
volume = "112",
pages = "29--34",
journal = "Early Human Development",
issn = "0378-3782",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Risk factors of metabolic bone disease of prematurity

AU - Ukarapong, Supamit

AU - Venkatarayappa, Sunil Kumar Batlahally

AU - Navarrete, Cristina

AU - Berkovitz, Gary

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective To identify the factors that increase risk of metabolic bone disease of prematurity (MBD). Study design A retrospective case-control study of infants born between January 2013–April 2014 with gestation age < 30 weeks and birth weight < 1000 g. MBD was defined as serum alkaline phosphatase above 500 U/L and characteristic radiographic changes. Information was obtained on the presence of specific comorbidities. Results Of 76 infants evaluated, 40 met criteria for MBD. Median gestational age was 25 weeks in both groups (p = 0.512). Median birth weight of infants with MBD was significantly lower than that of controls (560 vs. 765 g, p < 0.01). Longer period of parenteral nutrition and dexamethasone use was observed in MBD group. Cholestasis was associated with the highest likelihood of MBD (OR 16.6, 95% CI 4.8–56.9). Seizures (OR 5.2, 95% CI 1.3–20.5) and the prolonged use of diuretics (OR 2.6, 95% CI 1.0–7.0) also significantly increased the likelihood of MBD. Only cholestasis remained significant (OR 9.6, 95% CI 2.1–45.3) after multiple regression analysis. Conclusion Cholestasis is a significant risk factor for the development of MBD. Our future studies will be directed towards determining the causal relationship between cholestasis and MBD.

AB - Objective To identify the factors that increase risk of metabolic bone disease of prematurity (MBD). Study design A retrospective case-control study of infants born between January 2013–April 2014 with gestation age < 30 weeks and birth weight < 1000 g. MBD was defined as serum alkaline phosphatase above 500 U/L and characteristic radiographic changes. Information was obtained on the presence of specific comorbidities. Results Of 76 infants evaluated, 40 met criteria for MBD. Median gestational age was 25 weeks in both groups (p = 0.512). Median birth weight of infants with MBD was significantly lower than that of controls (560 vs. 765 g, p < 0.01). Longer period of parenteral nutrition and dexamethasone use was observed in MBD group. Cholestasis was associated with the highest likelihood of MBD (OR 16.6, 95% CI 4.8–56.9). Seizures (OR 5.2, 95% CI 1.3–20.5) and the prolonged use of diuretics (OR 2.6, 95% CI 1.0–7.0) also significantly increased the likelihood of MBD. Only cholestasis remained significant (OR 9.6, 95% CI 2.1–45.3) after multiple regression analysis. Conclusion Cholestasis is a significant risk factor for the development of MBD. Our future studies will be directed towards determining the causal relationship between cholestasis and MBD.

KW - Bone

KW - Preterm infant

KW - Risk factor and comorbidities

UR - http://www.scopus.com/inward/record.url?scp=85021692289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021692289&partnerID=8YFLogxK

U2 - 10.1016/j.earlhumdev.2017.06.010

DO - 10.1016/j.earlhumdev.2017.06.010

M3 - Article

VL - 112

SP - 29

EP - 34

JO - Early Human Development

JF - Early Human Development

SN - 0378-3782

ER -